Our Spring to GIST Awareness Day Campaign Continues! Our spring fundraising campaign is all about Fueling GIST Research and we will be sharing examples of all the ways The Life Raft Group is involved [...]
The Life Raft Group is thankful to those who so generously supported us in 2022 and we hope you continue to support our new initiatives in 2023. #thrivingtogether
One highlight of the "Rare Cancers: Great Unmet Medical Needs" CME Conference, hosted by Columbia University Herbert Irving Comprehensive Cancer Center and co-sponsored by the Jed Ian Taxel Foundation for Rare Cancer Research, was a presentation on sarcomas by Dr. Gary K. Schwartz, member of the LRG Medical Advisory Board.
The Life Raft Group celebrated GIST Awareness Day 2021 by holding an virtual, interactive Q&A session for SDH-deficient GIST patients with leading experts in the field.
The Connective Tissue Oncology Society (CTOS) meeting was held Nov 18-21st and was chaired by three women in the field. This year’s meeting special because it was held virtually due to COVID-19. One of the new aims of the CTOS organization is to incorporate the patient perspective in more of its sessions.
Dr. Nikhil Guhagarkar found opportunities to balance life as a father, husband, medical professional, patient advocate and cancer survivor.
The College of American Pathologists (CAP) released an updated version of its GIST Biopsy and Resection Cancer Protocols. Pathologists use CAP Cancer Protocols in the process of diagnosing a disease.
The Life Raft Group is pleased to announce a new partnership with SELNET, a project which is creating a multidisciplinary network of European and Latin American clinical and translational specialists. This project’s goal is to improve diagnosis and clinical care in sarcomas and establish guidelines for referral policies, diagnostic methods, clinical practice guidelines among other necessary changes to current practices.
The NCCN Foundation produces patient booklets that contain evidence-based disease information and important guidance to help patients formulate questions that are important to them. The Life Raft Group, a leading patient advocacy organization, is working with the Foundation to endorse these guidelines.
MyPART’s mission is to engage patients as partners in rare tumor research. As an advocacy partner, our aim is to improve the outcomes of patients with rare tumors and identify and engage patients through education and the dissemination of information.
